CureVac announced together with its collaboration partner GSK, first preclinical data in A Rat Model, Showing That Its Second-Generation Covid-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals
CureVac Announces Second-generation Covid-19 Vacci | 15/05/2021 | By Darshana | 202
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy